About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

The State Council issued its approval of the "15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine," agreeing in principle to the plan.

2026-07-10

The State Council issued its approval of the "15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine," agreeing in principle to the plan.

Other News
2026-07-10

Andy Burnham secured nominations from 322 of Labour’s 403 MPs on the first day of the party’s leadership contest, making him the clear favorite to replace Keir Starmer and assume the role of UK prime minister. Burnham said he was grateful for colleag

Andy Burnham secured nominations from 322 of Labour’s 403 MPs on the first day of the party’s leadership contest, making him the clear favorite to replace Keir Starmer and assume the role of UK prime minister. Burnham said he was grateful for colleagues’ support and outlined plans to devolve power away from Westminster, reshape the economic model and promote broader-based growth. Rival candidates failed to reach the 81-MP nomination threshold; Burnham needs one more nomination to become the sole candidate. The leadership contest closes July 17 and he is expected to take office July 20. Starmer will not participate in the nomination vote by convention.
2026-07-10

Innovative drug-themed funds are performing strongly, with the Science and Technology Innovation Drug ETF Huatai and the Science and Technology Innovation Drug ETF Guotai both rising by more than 5%.

Innovative drug-themed funds are performing strongly, with the Science and Technology Innovation Drug ETF Huatai and the Science and Technology Innovation Drug ETF Guotai both rising by more than 5%.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.